newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

  • Ascentage Pharma presented initial clinical data for alrizomadlin (APG-115) as monotherapy or combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma or soft-tissue sarcomas at the 2026 ASCO Annual Meeting.
  • Alrizomadlin monotherapy showed preliminary antitumor activity with one pediatric patient achieving a complete response in rhabdomyosarcoma.
  • The combination of alrizomadlin & lisaftoclax yielded an objective response rate of 23.5% among 17 response-evaluable patients, including one complete response in Ewing sarcoma & three partial responses.
  • The regimen demonstrated a manageable safety profile with no dose-limiting toxicities, treatment-related deaths, or discontinuations; adverse events were primarily gastrointestinal & hematologic.
  • Alrizomadlin is an orally administered MDM2-p53 inhibitor & the first investigational agent of its class to enter clinical development in China, with potential for global first-in-class status.
  • The drug is included in China's "SPARK Plan" for pediatric solid tumor development, covering neuroblastoma, rhabdomyosarcoma, & Ewing sarcoma.
  • Ascentage Pharma made its ninth consecutive appearance at ASCO, presenting six studies involving three key assets, including three rapid oral presentations.
  • The Company continues to advance clinical studies with the goal of providing new treatment options for pediatric patients with unmet medical needs.